top of page

Selected Readings

Yaden DB, Nayak SM, Gukasyan N, Anderson BT, Griffiths RR. The Potential of Psychedelics for End of Life and Palliative Care. Curr Top Behav Neurosci. 2022;56:169-184. doi: 10.1007/7854_2021_278. PMID: 34958455.


Bahji, A., Zarate, C. A., Vazquez, G. H. (2022). Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. Expert Opin Drug Saf. (06/21/22). 853-866. DOI: 10.1080/14740338.2022.2047928

Katzman, J. (2018). Rapid depression remission and the “therapeutic bends” with ketamine-assisted psychotherapy. Psychedelics Today.

Oaklander, M. (2017). New hope for depression. TIME.

Dore, J., Turnipseed, B., Dwyer, S., Turnipseed, A., Andries, J., Ascani, G., Monnette, C., Huidekoper, A., Strauss, N., & Wolfson, P. (2019). Ketamine assisted psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy, Journal of Psychoactive Drugs, 51(2), 189-198. DOI: 10.1080/02791072.2019.1587556

bottom of page